NR4A1 and breast cancer: Regarding the breast cancer subtype, the prevalence of hormone receptor-positive cases was 44.7%, which is much lower than the results found in other developed countries in Asia, Europe and the US: 71% in Japan (Shibuta et al., 2011), 62% in Taiwan (Lin et al., 2009), 72% in Europe (Blows et al., 2010), and 72.7% in the US (Howlader et al., 2014).